trazodone has been researched along with Chronic Disease in 10 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Six middle aged subjects complaining of chronic insomnia associated with dysthymia were investigated in a 2-month single blind study: a 7-day placebo treatment period, followed by a 6-week phase with increasing doses of trazodone controlled release (CR) formulation (50 mg through days 8-10; 75 mg through days 11-13; 150 mg through days 14-49) and then a final 7-day withdrawal period under placebo." | 9.07 | Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. ( Boselli, M; Di Giovanni, G; Parrino, L; Spaggiari, MC; Terzano, MG, 1994) |
| "The study examined whether adjunctive treatment with trazodone would reduce negative symptomatology in patients with chronic, residual schizophrenia." | 9.07 | Adjunctive trazodone in the treatment of negative symptoms of schizophrenia. ( Bocola, V; Decina, P; Hadjichristos, C; Mukherjee, S; Saraceni, F; Scapicchio, P, 1994) |
| "Six middle aged subjects complaining of chronic insomnia associated with dysthymia were investigated in a 2-month single blind study: a 7-day placebo treatment period, followed by a 6-week phase with increasing doses of trazodone controlled release (CR) formulation (50 mg through days 8-10; 75 mg through days 11-13; 150 mg through days 14-49) and then a final 7-day withdrawal period under placebo." | 5.07 | Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. ( Boselli, M; Di Giovanni, G; Parrino, L; Spaggiari, MC; Terzano, MG, 1994) |
| "The study examined whether adjunctive treatment with trazodone would reduce negative symptomatology in patients with chronic, residual schizophrenia." | 5.07 | Adjunctive trazodone in the treatment of negative symptoms of schizophrenia. ( Bocola, V; Decina, P; Hadjichristos, C; Mukherjee, S; Saraceni, F; Scapicchio, P, 1994) |
| "Bupropion SR in the treatment of PTSD had no significant effect in the current sample." | 2.73 | A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. ( Becker, ME; Beckham, JC; Bukenya, DS; Dennis, MF; Hertzberg, MA; Moore, SD, 2007) |
| "Chronic pain is refractory to most currently marketed regimens." | 2.66 | Chronic pain: hypothesized mechanism and rationale for treatment. ( Gershon, S, 1986) |
| " Some participants expressed concern at the lack of data for this practice, particularly the absence of dose-response and tolerance information, and noted that the small amount of efficacy data available is not encouraging." | 1.32 | The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. ( Buysse, DJ; Cassella, J; Mendelson, WB; Meyer, RE; Roehrs, T; Roth, T; Walsh, JK; Woods, JH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Apgar, BS | 1 |
| Mendelson, WB | 1 |
| Roth, T | 1 |
| Cassella, J | 1 |
| Roehrs, T | 1 |
| Walsh, JK | 1 |
| Woods, JH | 1 |
| Buysse, DJ | 1 |
| Meyer, RE | 1 |
| Becker, ME | 1 |
| Hertzberg, MA | 1 |
| Moore, SD | 1 |
| Dennis, MF | 1 |
| Bukenya, DS | 1 |
| Beckham, JC | 1 |
| Parrino, L | 1 |
| Spaggiari, MC | 1 |
| Boselli, M | 1 |
| Di Giovanni, G | 1 |
| Terzano, MG | 1 |
| Decina, P | 1 |
| Mukherjee, S | 1 |
| Bocola, V | 1 |
| Saraceni, F | 1 |
| Hadjichristos, C | 1 |
| Scapicchio, P | 1 |
| Tammiala-Salonen, T | 1 |
| Forssell, H | 1 |
| Fabre, LF | 1 |
| Gershon, S | 1 |
| Conigliaro, S | 1 |
| Rosà , R | 1 |
| Osimo, F | 1 |
| Fumagalli, E | 1 |
| Cavaliere, G | 1 |
| Arrigo, G | 1 |
| Ventafridda, V | 1 |
| Bonezzi, C | 1 |
| Caraceni, A | 1 |
| De Conno, F | 1 |
| Guarise, G | 1 |
| Ramella, G | 1 |
| Saita, L | 1 |
| Silvani, V | 1 |
| Tamburini, M | 1 |
| Toscani, F | 1 |
1 review available for trazodone and Chronic Disease
| Article | Year |
|---|---|
United States experience and perspectives with trazodone.
Topics: Aged; Bulimia; Chronic Disease; Clinical Trials as Topic; Depressive Disorder; Female; Humans; Male; | 1989 |
7 trials available for trazodone and Chronic Disease
| Article | Year |
|---|---|
A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Attention; Bupropion; Chronic | 2007 |
Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia.
Topics: Adult; Chronic Disease; Delayed-Action Preparations; Depressive Disorder; Female; Humans; Male; Midd | 1994 |
Adjunctive trazodone in the treatment of negative symptoms of schizophrenia.
Topics: Analysis of Variance; Antipsychotic Agents; Case-Control Studies; Chemotherapy, Adjuvant; Chronic Di | 1994 |
Trazodone in burning mouth pain: a placebo-controlled, double-blind study.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Burning Mouth Syndrome; | 1999 |
United States experience and perspectives with trazodone.
Topics: Aged; Bulimia; Chronic Disease; Clinical Trials as Topic; Depressive Disorder; Female; Humans; Male; | 1989 |
Chronic pain: hypothesized mechanism and rationale for treatment.
Topics: Antidepressive Agents; Brain; Chronic Disease; Clinical Trials as Topic; Depression; Humans; Neurotr | 1986 |
Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone.
Topics: Adult; Aged; Amitriptyline; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Humans; | 1987 |
3 other studies available for trazodone and Chronic Disease
| Article | Year |
|---|---|
Challenges of fragmented care in long-term management of pelvic pain.
Topics: Acetaminophen; Adult; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Chr | 2007 |
The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Depressive Disorder, Major; Dose-Response | 2004 |
[Chronic headache].
Topics: Acetylglucosaminidase; Adult; Aged; Aminopeptidases; CD13 Antigens; Chronic Disease; Female; Headach | 1987 |